CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The SCANRESIST project focuses on validating SCO-101, a new drug targeting resistance mechanisms in breast cancer. This clinical trial aims to establish the drug's effectiveness and safety, paving the way for partnerships with pharmaceutical companies for further development.
Worldwide in 2018, cancer has been responsible for around 9.6 million deaths, and with a prediction of a further increase in incidence over the next years – which calls for urgent better treatment modalities to combat such deadly disease.
Resistance to anticancer therapy is considered the main obstacle to successful clinical management of cancer patients.
Scandion Oncology A/S (SCANDION) is a clinical-stage biotechnology company aimed to solve the anti-cancer drug resistance problem.
We are deve…
SCANDION ONCOLOGY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
